TABLE 2.
Baseline Clinical Characteristics
| Characteristic | Full Population | Virologically Stable | Virologically + Clinically Stable | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Switchers (n = 927) | Nonswitchersa (n = 18,511, weighted n = 927) | P Valueb | Switchers (n = 168) | Nonswitchersa (n = 3,301, weighted n = 168) | P Valueb | Switchers (n = 55) | Nonswitchersa (n = 1,100, weighted (n = 55) | P Valueb | |
| Charlson comorbidity score category, n (%)c | |||||||||
| 0 | 93 (10.0) | 139 (15.0) | < 0.001 | 15 (8.9) | 18 (10.9) | 0.441 | 10 (18.2) | 6 (10.2) | 0.068 |
| 1-2 | 3 (0.3) | 10 (1.1) | 0.040 | 2 (1.2) | 1 (0.8) | 0.634 | 1 (1.8) | 1 (1.0) | 0.568 |
| 3-4 | 674 (72.7) | 658 (71.0) | 0.267 | 118 (70.2) | 124 (73.6) | 0.339 | 40 (72.7) | 42 (75.6) | 0.639 |
| 5+ | 157 (16.9) | 120 (12.9) | < 0.001 | 33 (19.6) | 25 (14.7) | 0.085 | 4 (7.3) | 7 (13.3) | 0.207 |
| Years of treatment pre-index, mean (SD) | 1.8 (1.2) | 1.8 (1.2) | 0.962 | 2.0 (1.1) | 2.0 (1.1) | 0.991 | 1.9 (1.1) | 1.9 (1.1) | 0.996 |
| Antiretroviral treatment regimen,d n (%)c | |||||||||
| EFV + TDF + FTC | 400 (43.2) | 603 (65.1) | < 0.001 | 71 (42.3) | 106 (63.2) | < 0.001 | 14 (25.5) | 34 (61.3) | < 0.001 |
| ATV/r + TDF + FTC | 127 (14.9) | 63 (7.8) | < 0.001 | 25 (14.9) | 8 (4.8) | < 0.001 | 12 (21.8) | 3 (4.9) | < 0.001 |
| RAL + TDF + FTC | 76 (8.2) | 48 (5.2) | < 0.001 | 13 (7.7) | 9 (5.3) | 0.178 | 9 (16.4) | 3 (5.4) | 0.001 |
| DRV/r + TDF + FTC | 62 (6.7) | 43 (4.7) | 0.005 | 7 (4.2) | 10 (5.7) | 0.425 | 3 (5.5) | 3 (5.6) | 0.955 |
| LPV/r + TDF + FTC | 77 (8.3) | 25 (2.7) | < 0.001 | 17 (10.1) | 4 (2.4) | < 0.001 | 5 (9.1) | 1 (2.3) | 0.004 |
| RPV + TDF + FTC | 25 (2.7) | 37 (4.0) | 0.049 | 4 (2.4) | 10 (6.1) | 0.053 | 2 (3.6) | 4 (7.9) | 0.257 |
| NVP + TDF + FTC | 26 (2.8) | 18 (1.9) | 0.056 | 5 (3.0) | 5 (3.0) | 0.987 | 2 (3.6) | 2 (3.2) | 0.852 |
| EFV + AZT + LAM | 25 (2.7) | 9 (1.0) | < 0.001 | 3 (1.8) | 2 (1.2) | 0.470 | 2 (3.6) | 0 (0.8) | 0.029 |
aMeans, SDs, counts, and percentages for nonswitchers are weighted and normalized to the matched switcher cohort.
bP values are adjusted using a robust (sandwich) variance estimate to account for correlation due to multiple observations per patient.
cBecause of rounding, percentages may not sum to 100%.
dOnly regimens used by ≥ 2.0% of the full study population are listed.
ATV = atazanavir; AZT = azidothymidine; DRV = darunavir; EFV = efavirenz; FTC = emtricitabine; LAM = lamivudine; LPV = lopinavir; NVP = nevirapine; r = low-dose ritonavir; RAL = raltegravir; RPV = rilpivirine; SD = standard deviation; TDF = tenofovir disoproxil fumarate.